Quantum BioPharma Ltd.

QNTM·NasdaqCM·Healthcare
Compare
2.8200−0.1200 (−4.08%)today
At close: Oct 12, 4:00 PM EDT · May be delayed up to 15 min · USD
After hours2.9700+0.1500 (+5.32%)Oct 12, 7:37 PM EDT

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close2.9400
Open2.9800
Day range2.80003.0000
52-week range2.070016.3600
Off day high−6.00%
Off 52-week high−82.76%
Volume156.80K
Avg. volume (3M)205.51K
Market cap18.13M
EPS (TTM)-4.98
Forward P/E-0.36
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)0.38
Shares outstanding6.43M
Short interest4.82% of float
Earnings dateAug 12, 2025 (est.)
Analyst target12.2247
Profit margin0.00%

Against its peers

Compare in full ›
QNTM JUNS SILO NRSN ENVB PMN
Market cap 18.13M 4.01M 3.06M 6.60M 6.58M 84.74M
P/E (TTM) — — — — — —
Forward P/E -0.4 50.7 -2.1 -0.5 -1.0 -2.1
Price/book 2.7 -5.5 0.3 -3.6 0.7 1.7
Dividend yield — — — — — —
1-year change −80.65% −97.38% −84.39% −85.00% −81.30% −19.92%
Today −4.08% +6.67% +1.36% −4.92% +1.38% −1.66%

The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.

Latest news

All QNTM news ›
TradingView·Positive

Net debt of Quince Therapeutics, Inc. – NASDAQ:IRLA

Quince Therapeutics, Inc. is a biopharmaceutical company, which engages in unlocking the power of a patient’s biology for the treatment of rare diseases. Its product includes eDSP, developed using their proprietary Autologous Intracellular…

Mugglehead·Positive

Quantum BioPharma signs Thermo Fisher contract for Phase 2 MS trial

Quantum said on Oct. 6 it had entered a Study Start-Up Agreement; it gave no first-dose or readout date. In its Oct. 6 release, Quantum called the contract a Study Start-Up Agreement. Thermo Fisher's PPD clinical research business will…

Stock Titan·

Karyopharm: Anders Hove reports 4.5% ownership

Two Acorn funds account for one manager’s reported stake in Karyopharm (KPTI). Stock Titan - [SCHEDULE 13G/A] Karyopharm Therapeutics Inc. Amended Passive Investment Disclosure Karyopharm: Anders Hove reports 4.5% ownership Reported…

@StockTitan_net·Positive

Quantum BioPharma signs Phase 2 Lucid-MS trial deal

The planned study will assess Lucid-MS in progressive MS using clinical and radiological endpoints. Quantum BioPharma Ltd. (QNTM) entered into a Study Start-Up Agreement with Thermo Fisher Scientific’s clinical research business to…

From articles in the 4Search news index.

In the news

23mentions in 30 days
13with it in the headline
Positivesentiment

Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 23 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Search index. Terms of use.